{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:01:12Z","timestamp":1780977672989,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07317-x","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:50:38Z","timestamp":1780977038000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sub-retinal pigment epithelium features as predictors for limited interval extension of faricimab in treatment-na\u00efve neovascular age-related macular degeneration"],"prefix":"10.1007","author":[{"given":"Keiko","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuto","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle A","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"7317_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, Group MS (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"7317_CR2","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser P, Nguyen Q, Kirchhof B, Ho A, Ogura Y, Yancopoulos G, Stahl N, Vitti R, Berliner A, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"7317_CR3","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S, investigators As (2021) Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the aries study: a randomized clinical trial. Retina 41:1911\u20131920. https:\/\/doi.org\/10.1097\/IAE.0000000000003128","journal-title":"Retina"},{"key":"7317_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","volume":"37","author":"D Rosenberg","year":"2023","unstructured":"Rosenberg D, Deonarain DM, Gould J, Sothivannan A, Phillips MR, Sarohia GS, Sivaprasad S, Wykoff CC, Cheung CMG, Sarraf D, Bakri SJ, Chaudhary V (2023) Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis. Eye (Lond) 37:6\u201316. https:\/\/doi.org\/10.1038\/s41433-022-02020-7","journal-title":"Eye (Lond)"},{"key":"7317_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06519-5","author":"H Ota","year":"2024","unstructured":"Ota H, Kataoka K, Asai K, Takeuchi J, Nakano Y, Nakamura K, Todoroki T, Nishiguchi KM (2024) Five-year outcomes of treat and extend regimen using intravitreal aflibercept injection for treatment-naive age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. https:\/\/doi.org\/10.1007\/s00417-024-06519-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7317_CR6","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","volume":"123","author":"FG Holz","year":"2016","unstructured":"Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, Larsen M, Weichselberger A, Wenzel A, Schmidt A, Escher D, Sararols L, Souied E (2016) Single-chain antibody fragment vegf inhibitor rth258 for neovascular age-related macular degeneration a randomized controlled study. Ophthalmology 123:1080\u20131089. https:\/\/doi.org\/10.1016\/j.ophtha.2015.12.030","journal-title":"Ophthalmology"},{"key":"7317_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"JT Regula","year":"2016","unstructured":"Regula JT, von Lundh P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G (2016) Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 8:1265\u20131288. https:\/\/doi.org\/10.15252\/emmm.201505889","journal-title":"EMBO Mol Med"},{"key":"7317_CR8","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","volume":"112","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, Greene WL, Shams N (2005) Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112:1048\u20131053. https:\/\/doi.org\/10.1016\/j.ophtha.2005.01.043","journal-title":"Ophthalmology"},{"key":"7317_CR9","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 99:11393\u201311398. https:\/\/doi.org\/10.1073\/pnas.172398299","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7317_CR10","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/jcp.10442","volume":"199","author":"Y Oshima","year":"2004","unstructured":"Oshima Y, Deering T, Oshima S, Nambu H, Reddy PS, Kaleko M, Connelly S, Hackett SF, Campochiaro PA (2004) Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J Cell Physiol 199:412\u2013417. https:\/\/doi.org\/10.1002\/jcp.10442","journal-title":"J Cell Physiol"},{"key":"7317_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cyto.2007.09.001","volume":"40","author":"S Peters","year":"2007","unstructured":"Peters S, Cree IA, Alexander R, Turowski P, Ockrim Z, Patel J, Boyd SR, Joussen AM, Ziemssen F, Hykin PG, Moss SE (2007) Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability. Cytokine 40:144\u2013150. https:\/\/doi.org\/10.1016\/j.cyto.2007.09.001","journal-title":"Cytokine"},{"key":"7317_CR12","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","volume":"14","author":"R Mukai","year":"2024","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T (2024) One-year outcomes and safety assessment of faricimab in treatment-naive patients with neovascular age-related macular degeneration in Japan. Sci Rep 14:11681. https:\/\/doi.org\/10.1038\/s41598-024-62559-1","journal-title":"Sci Rep"},{"key":"7317_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-024-01115-w","author":"AF Sajiki","year":"2024","unstructured":"Sajiki AF, Kataoka K, Takeuchi J, Ota H, Nakano Y, Horiguchi E, Kaneko H, Terasaki H, Ito Y, Nishiguchi KM (2024) Clinical utility of swept-source optical coherence tomography angiography for the diagnosis of exudative maculopathy. Jpn J Ophthalmol. https:\/\/doi.org\/10.1007\/s10384-024-01115-w","journal-title":"Jpn J Ophthalmol"},{"key":"7317_CR14","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1097\/IAE.0000000000002760","volume":"40","author":"A Fujita","year":"2020","unstructured":"Fujita A, Kataoka K, Takeuchi J, Nakano Y, Horiguchi E, Kaneko H, Ito Y, Terasaki H (2020) Diagnostic characteristics of polypoidal choroidal vasculopathy based on b-scan swept-source optical coherence tomography angiography and its interrater agreement compared with indocyanine green angiography. Retina 40:2296\u20132303. https:\/\/doi.org\/10.1097\/IAE.0000000000002760","journal-title":"Retina"},{"key":"7317_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7275\/tbfa-x148","volume":"20","author":"D Sharpe","year":"2015","unstructured":"Sharpe D (2015) Your chi-square test is statistically significant: Now what? Practical Assess Res Eval 20:1\u20131 https:\/\/doi.org\/10.7275\/tbfa-x148","journal-title":"Practical Assessment, Research, and Evaluation"},{"key":"7317_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.survophthal.2020.05.003","volume":"66","author":"KX Cheong","year":"2021","unstructured":"Cheong KX, Teo KYC, Cheung CMG (2021) Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration. Surv Ophthalmol 66:68\u201397. https:\/\/doi.org\/10.1016\/j.survophthal.2020.05.003","journal-title":"Surv Ophthalmol"},{"key":"7317_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/IAE.0000000000003935","volume":"44","author":"D Sarraf","year":"2024","unstructured":"Sarraf D, Khanani AM, Sadda SR, Chang A, Wong DT, Kempf AS, Saffar I, Tang S, Tadayoni R (2024) Pigment epithelial detachment thickness and variability affects visual outcomes in patients with neovascular age-related macular degeneration. Retina 44:10\u201319. https:\/\/doi.org\/10.1097\/IAE.0000000000003935","journal-title":"Retina"},{"key":"7317_CR18","doi-asserted-by":"publisher","unstructured":"Shah P, Rafijah N, Tang Y, Sivaprasad S, Mathis T, Margaron P, Kotecha A (2024) Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD). BMJ Open Ophthalmol 9. https:\/\/doi.org\/10.1136\/bmjophth-2024-001855","DOI":"10.1136\/bmjophth-2024-001855"},{"key":"7317_CR19","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1038\/s41598-024-52448-y","volume":"14","author":"K Sayanagi","year":"2024","unstructured":"Sayanagi K, Fujimoto S, Hara C, Fukushima Y, Maruyama K, Kawasaki R, Sato S, Nishida K (2024) Effect of polyp regression and reduction on treatment efficacy in polypoidal choroidal vasculopathy treated with aflibercept. Sci Rep 14:1833. https:\/\/doi.org\/10.1038\/s41598-024-52448-y","journal-title":"Sci Rep"},{"key":"7317_CR20","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1007\/s00417-023-06116-y","volume":"261","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Nagashima T, Akiyama H (2023) Short-term outcomes of intravitreal faricimab for treatment-naive neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 261:2945\u20132952. https:\/\/doi.org\/10.1007\/s00417-023-06116-y","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7317_CR21","doi-asserted-by":"publisher","first-page":"8747","DOI":"10.1038\/s41598-023-35759-4","volume":"13","author":"R Mukai","year":"2023","unstructured":"Mukai R, Kataoka K, Tanaka K, Miyara Y, Maruko I, Nakayama M, Watanabe Y, Yamamoto A, Wakatsuki Y, Onoe H, Wakugawa S, Terao N, Hasegawa T, Hashiya N, Kawai M, Maruko R, Itagaki K, Honjo J, Okada AA, Mori R, Koizumi H, Iida T, Sekiryu T (2023) Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan. Sci Rep 13:8747. https:\/\/doi.org\/10.1038\/s41598-023-35759-4","journal-title":"Sci Rep"},{"key":"7317_CR22","doi-asserted-by":"publisher","first-page":"104795","DOI":"10.1016\/j.jfo.2026.104795","volume":"49","author":"A Posnic","year":"2026","unstructured":"Posnic A, Vaast M, Poinas A, Le Pabic E, Bellamy JP, Delhay C, Faure S, Le Rouic JF, Henry A, Lebreton O, Masse H, Guillaumie T, Fournier I, Mainguy A, Le Lez ML, Khanna RK, George A, Pipelart V, Bernard Y, Grimbert P, Mazhar D, Benzerroug M, Briend B, Clement M, Jammes-Veaux HP, Posnic MP, Bonissent A, Guyot C, Rousseau N, Van Dam T, Bellot B, Ferron L, Le Meur R, Mouriaux G, Weber F, Maucourant M, Ducloyer Y JB (2026) Extension of the intravitreal injection interval after switching to faricimab in patients with exudative AMD: The multicenter FAR WEST study. J Fr Ophtalmol 49:104795. https:\/\/doi.org\/10.1016\/j.jfo.2026.104795","journal-title":"J Fr Ophtalmol"},{"key":"7317_CR23","doi-asserted-by":"publisher","first-page":"44717","DOI":"10.1038\/s41598-025-28911-9","volume":"15","author":"S Inoda","year":"2025","unstructured":"Inoda S, Takahashi H, Hashimoto Y, Yoshida H, Takahashi H, Takayama T, Tsuchiya S, Matsumoto D, Kawashima H, Kaburaki T, Yanagi Y (2025) One year outcomes of intravitreal faricimab for treatment Na\u00efve neovascular AMD and associations with baseline aqueous humor cytokines. Sci Rep 15:44717. https:\/\/doi.org\/10.1038\/s41598-025-28911-9","journal-title":"Sci Rep"},{"key":"7317_CR24","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY, Investigators TL (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"7317_CR25","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R, Tenaya, Investigators L (2024) TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology 131:914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"7317_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10384-017-0556-3","volume":"62","author":"A Tsujikawa","year":"2018","unstructured":"Tsujikawa A, Akagi-Kurashige Y, Yuzawa M, Ishibashi T, Nakanishi H, Nakatani E, Teramukai S, Fukushima M, Yoshimura N, Group AS (2018) Baseline data from a multicenter, 5-year, prospective cohort study of Japanese age-related macular degeneration: an AMD2000 report. Jpn J Ophthalmol 62:127\u2013136. https:\/\/doi.org\/10.1007\/s10384-017-0556-3","journal-title":"Jpn J Ophthalmol"},{"key":"7317_CR27","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s10384-025-01240-0","volume":"69","author":"T Iida","year":"2025","unstructured":"Iida T, Gomi F, Yasukawa T, Yamashiro K, Honda S, Maruko I, Kataoka K, Japanese Retina and Vitreous Society Guidelines Committee for Neovascular Age-Related Macular Degeneration (2025) Japanese clinical guidelines for neovascular age-related macular degeneration. Jpn J Ophthalmol 69:639\u2013660. https:\/\/doi.org\/10.1007\/s10384-025-01240-0","journal-title":"Jpn J Ophthalmol"},{"key":"7317_CR28","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/biomedicines13122909","volume":"13","author":"A Machida","year":"2025","unstructured":"Machida A, Kurihara J, Hirata Y, Machida E, Murakami R, Oka A, Yoneda A, Tsuiki E, Oishi A (2025) Flexible loading phase treat-and-extend regimen with faricimab for neovascular age-related macular degeneration: a real-world study. Biomedicines 13:2909. https:\/\/doi.org\/10.3390\/biomedicines13122909","journal-title":"Biomedicines"},{"key":"7317_CR29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.oret.2020.03.010","volume":"4","author":"I Maruko","year":"2020","unstructured":"Maruko I, Ogasawara M, Yamamoto A, Itagaki K, Hasegawa T, Arakawa H, Nakayama M, Koizumi H, Okada AA, Sekiryu T, Iida T (2020) Two-year outcomes of treat-and-extend intravitreal aflibercept for exudative age-related macular degeneration: a prospective study. Ophthalmol Retina 4:767\u2013776. https:\/\/doi.org\/10.1016\/j.oret.2020.03.010","journal-title":"Ophthalmol Retina"},{"key":"7317_CR30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.oret.2023.06.002","volume":"7","author":"K Yoneda","year":"2023","unstructured":"Yoneda K, Takeuchi M, Yasukawa T, Terasaki H, Yamamoto Y, Jujo T, Wakuta M, Matsubara H, Mitamura Y, Kato A, Kondo M, Kimura K, Takagi H, Gomi F, Sakamoto T, Japanese Clinical Retinal Study G (2023) Anti-VEGF treatment strategies for 3 subtypes of neovascular age-related macular degeneration in a clinical setting: A multicenter cohort study in Japan. Ophthalmol Retina 7:869\u2013878. https:\/\/doi.org\/10.1016\/j.oret.2023.06.002","journal-title":"Ophthalmol Retina"},{"key":"7317_CR31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.oret.2017.03.003","volume":"1","author":"U Chakravarthy","year":"2017","unstructured":"Chakravarthy U, Bailey C, Brown D, Campochiaro P, Chittum M, Csaky K, Tufail A, Yates P, Cech P, Giraudon M, Delmar P, Szczesny P, Sahni J, Boulay A, Nagel S, Furst-Recktenwald S, Schwab D (2017) Phase I trial of anti-vascular endothelial growth factor\/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration. Ophthalmol Retina 1:474\u2013485. https:\/\/doi.org\/10.1016\/j.oret.2017.03.003","journal-title":"Ophthalmol Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07317-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07317-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07317-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:50:44Z","timestamp":1780977044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07317-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":31,"alternative-id":["7317"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07317-x","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted in accordance with the guidelines of the Helsinki Declaration. The Institutional Review Board of Kyorin University (approval number: 2380).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Keiko Kataoka reports a research grant from Chugai Pharmaceutical for the conduct of this study. She also reports personal fees (honoraria) from Santen Pharma, Bayer Pharma, Senju Pharma, Boehringer Ingelheim Japan, Otsuka Pharma, Canon Medtech, Zeiss, Chugai Pharma, Novartis Pharma, and Roche. Yuto Watanabe reports financial support from Chugai Pharma. Akiko Yamamoto reports personal fees (honoraria) from Novartis Pharma, Bayer, and Chugai Pharma. Annabelle A. Okada reports financial support from Alcon Pharma, Bayer Pharma, Pfizer, and Santen Pharma; consultancy fees from 4D Molecular Therapeutics, Apellis, Allergan Japan, Astellas Pharma, Bayer Consumer Care AG, Bayer Pharma, Chugai Pharma, Daiichi Sankyo, Kowa, and Ocular Therapeutix; and personal fees (honoraria) from Bayer Pharma, Chugai Pharma, Kowa, Mitsubishi Tanabe Pharma, Novartis Pharma, Otsuka Pharma, Santen Pharma, and Senju Pharma. Mariko Kumagai and Rie Ko declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}